GSK BEconneCTD-ILD Patient
A study for patients with interstitial lung disease (ILD) associated with CTD
About GSK BEconneCTD-ILD Patient
This app has been exclusively created for participants in the medical study for GSK BE-conneCTD ILD 221672. It contains Televisit functionality and allows participants to complete questionnaires.
A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connected tissue disease (CTD).
Similar Apps
Medable
Medable is on a mission to enable effective therapies to people faster....
J1I-MC-GZQD
This app has been exclusively created for participants in the medical study...
Avanti
For invited Avanti study participants. You will use this app to consent...
GSK 219685
This app has been created exclusively for participants in the medical study...
GSK 219855 France
You are invited to participate in the GSK BLISSc-ILD OLE study. This...
GSK 221458
This app is specifically intended for participants in the GSK 221458 study...
